Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.
The Next Generation Sequencing (NGS) field has been in constant flux since a wave of newcomers entered the field several years ago that changed the game. The startups offered sequencing users new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback